166 related articles for article (PubMed ID: 33368569)
1. A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.
Rombout-Sestrienkova E; Winkens B; van Kraaij M; van Deursen CTBM; Janssen MCH; Rennings AMJ; Evers D; Kerkhoffs JL; Masclee A; Koek GH
J Clin Apher; 2021 Jun; 36(3):340-347. PubMed ID: 33368569
[TBL] [Abstract][Full Text] [Related]
2. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.
Rombout-Sestrienkova E; Nieman FH; Essers BA; van Noord PA; Janssen MC; van Deursen CT; Bos LP; Rombout F; van den Braak R; de Leeuw PW; Koek GH
Transfusion; 2012 Mar; 52(3):470-7. PubMed ID: 21848963
[TBL] [Abstract][Full Text] [Related]
3. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.
Evers D; Kerkhoffs JL; Van Egmond L; Schipperus MR; Wijermans PW
J Clin Apher; 2014 Jun; 29(3):133-8. PubMed ID: 24130064
[TBL] [Abstract][Full Text] [Related]
4. Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: results from a randomized crossover trial.
Rombout-Sestrienkova E; Winkens B; Essers BA; Nieman FH; Noord PA; Janssen MC; van Deursen CT; Boonen A; Reuser-Kaasenbrood EP; Heeremans J; van Kraaij M; Masclee A; Koek GH
Transfusion; 2016 Jan; 56(1):261-70. PubMed ID: 26358375
[TBL] [Abstract][Full Text] [Related]
5. Course of iron parameters in HFE-hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomy.
Rombout-Sestrienkova E; Koek GH; Neslo R; van Kraaij M; Menheere PP; Masclee A; Swinkels DW
J Clin Apher; 2016 Dec; 31(6):564-570. PubMed ID: 26878994
[TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: report of 30 cases].
Poullin P; Lefèvre PA
Transfus Clin Biol; 2011 Dec; 18(5-6):553-8. PubMed ID: 22019606
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of erythrocytapheresis and low-dose erythropoietin for treatment of hemochromatosis.
Brückl D; Kamhieh-Milz S; Kamhieh-Milz J; Salama A
J Clin Apher; 2017 Jun; 32(3):170-174. PubMed ID: 27271482
[TBL] [Abstract][Full Text] [Related]
8. Erythrocytapheresis compared with whole blood phlebotomy for the treatment of hereditary haemochromatosis.
Sundic T; Hervig T; Hannisdal S; Assmus J; Ulvik RJ; Olaussen RW; Berentsen S
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s84-9. PubMed ID: 24333062
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study.
Rombout-Sestrienkova E; van Noord PA; van Deursen CT; Sybesma BJ; Nillesen-Meertens AE; Koek GH
Transfus Apher Sci; 2007 Jun; 36(3):261-7. PubMed ID: 17569592
[TBL] [Abstract][Full Text] [Related]
10. [Erythrocytapheresis for hereditary haemochromatosis].
Rombout-Sestrienkova E; van Deursen CT; Janssen MC; van Kraaij MG; de Leeuw PW; Koek GH
Ned Tijdschr Geneeskd; 2012; 156(26):A4745. PubMed ID: 22759710
[TBL] [Abstract][Full Text] [Related]
11. How we manage patients with hereditary haemochromatosis.
Rombout-Sestrienkova E; van Kraaij MG; Koek GH
Br J Haematol; 2016 Dec; 175(5):759-770. PubMed ID: 27723100
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of hereditary hemochromatosis: an update.
Kanwar P; Kowdley KV
Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):517-30. PubMed ID: 23985001
[TBL] [Abstract][Full Text] [Related]
13. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy in relation to blood volume and delta-hematocrit: an evaluation in hereditary hemochromatosis polycythemia vera and secondary erythrocytosis.
Evers D; Kerkhoffs JL; Van Egmond L; Wijermans PW
Transfus Apher Sci; 2013 Apr; 48(2):187. PubMed ID: 23809828
[No Abstract] [Full Text] [Related]
14. Erythrocytapheresis plus erythropoietin: an alternative therapy for selected patients with hemochromatosis and severe organ damage.
Mariani R; Pelucchi S; Perseghin P; Corengia C; Piperno A
Haematologica; 2005 May; 90(5):717-8. PubMed ID: 15921401
[TBL] [Abstract][Full Text] [Related]
15. The modified iron avidity index: a promising phenotypic predictor in HFE-related haemochromatosis.
Verhaegh PL; Moris W; Koek GH; van Deursen CT
Liver Int; 2016 Oct; 36(10):1535-9. PubMed ID: 26992127
[TBL] [Abstract][Full Text] [Related]
16. A comparison between erythrocytapheresis and venesection for the treatment of JAK2-mutated polycythaemia.
Ngo TQ; Scott MW; Sirdesai S; Hempton JL; Hodges GS; Campbell PJ
Intern Med J; 2024 Jun; 54(6):909-915. PubMed ID: 38145421
[TBL] [Abstract][Full Text] [Related]
17. Proton Pump Inhibitors Reduce the Frequency of Phlebotomy in Patients With Hereditary Hemochromatosis.
van Aerts RM; van Deursen CT; Koek GH
Clin Gastroenterol Hepatol; 2016 Jan; 14(1):147-52. PubMed ID: 26240005
[TBL] [Abstract][Full Text] [Related]
18. End-stage cardiomyopathy because of hereditary hemochromatosis successfully treated with erythrocytapheresis in combination with left ventricular assist device support.
Rombout-Sestrienkova E; De Jonge N; Martinakova K; Klöpping C; van Galen KP; Vink A; Wajon EM; Smit WM; van Bree C; Koek GH
Circ Heart Fail; 2014 May; 7(3):541-3. PubMed ID: 24847131
[No Abstract] [Full Text] [Related]
19. Evaluation of erythrocytapheresis compared to phlebotomy in polycythaemia vera patients.
Cabibbo S; Manenti GO; Antolino A; Poidomani M; Elia R; Palumbo G; DiRaimondo F
Hematol Transfus Cell Ther; 2023 Aug; ():. PubMed ID: 37718130
[TBL] [Abstract][Full Text] [Related]
20. Relationship of Baseline Hemoglobin Level with Serum Ferritin, Postphlebotomy Hemoglobin Changes, and Phlebotomy Requirements among HFE C282Y Homozygotes.
Mousavi SA; Mahmood F; Aandahl A; Knutsen TR; Llohn AH
Biomed Res Int; 2015; 2015():241784. PubMed ID: 26380265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
